about
WISP-3 inhibition of miR-452 promotes VEGF-A expression in chondrosarcoma cells and induces endothelial progenitor cells angiogenesis.Discovery of Novel Small Molecule Inhibitors of VEGF Expression in Tumor Cells Using a Cell-Based High Throughput Screening Platform.Matrix stiffening promotes a tumor vasculature phenotype.Placental growth factor signaling regulates isoform splicing of vascular endothelial growth factor A in the control of lung cancer cell metastasis.Rapamycin enhances the anti-angiogenesis and anti-proliferation ability of YM155 in oral squamous cell carcinoma.PlGF and VEGF-A Regulate Growth of High-Risk MYCN-Single Copy Neuroblastoma Xenografts via Different Mechanisms.Modulation of VEGF receptor 2 signaling by protein phosphatases.Vessel pruning or healing: endothelial metabolism as a novel target?Underlying Mechanisms for Distant Metastasis - Molecular Biology.Targeting neurokinin-3 receptor: a novel anti-angiogenesis strategy for cancer treatment.Sales for anti-angiogenic drugsVEGF-induced intracellular Ca2+ oscillations are down-regulated and do not stimulate angiogenesis in breast cancer-derived endothelial colony forming cells.Fibrocytes: A Novel Stromal Cells to Regulate Resistance to Anti-Angiogenic Therapy and Cancer Progression.In silico-based identification of human α-enolase inhibitors to block cancer cell growth metabolically.Inhibitory effect and molecular mechanism of mesenchymal stem cells on NSCLC cells.Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy.Endothelial Ca2+ Signaling and the Resistance to Anticancer Treatments: Partners in Crime.VEGF as a modulator of the innate immune response in glioblastoma.Immune Cell Metabolism in Tumor Microenvironment.Synergistic Activity for Natural and Synthetic Inhibitors of Angiogenesis Induced by Murine Sarcoma L-1 and Human Kidney Cancer Cells.Hydrogen peroxide regulates angiogenesis-related factors in tumor cells.Von Hippel-Lindau mutations disrupt vascular patterning and maturation via Notch.Rhodocetin-αβ selectively breaks the endothelial barrier of the tumor vasculature in HT1080 fibrosarcoma and A431 epidermoid carcinoma tumor models.A novel peptide specifically binding to VEGF receptor suppresses angiogenesis and
P2860
Q33889280-0C0EFAAC-3941-4F51-99C2-1708CB1DE6D4Q36228258-C69EB31D-1743-48C5-A671-DEFBF8B4CB3FQ37598974-87D03FA7-3FA8-4EFE-8702-E344E8C893D0Q38598362-4CEE8D63-3519-4B30-BD8E-9FE2B09304E6Q38700218-81F35D86-897C-473D-A79C-1A6988AF9754Q38743706-935E40A4-4C90-4E32-B39C-7C8299F3A169Q39020269-0BF5085A-E0F6-4E22-B612-EFB61860978CQ39024164-319FE136-F938-46A5-8529-2733AC06C1E8Q40102636-31FDA1D6-84DA-45EF-9BAA-F92F4AB97B5BQ41093430-89880152-EA63-4BA9-BC4E-AF5A5BAAB136Q42332290-D72FED7D-AB80-477F-8868-940CD180464CQ47137711-1F854ADB-BB0F-488B-B5BD-3DC754BBA158Q47668446-1FE877D5-7085-4E60-AF10-0399BAC5994CQ47698219-C6CB10CF-AAFA-4251-815A-75267E7F687FQ47830442-D29C0B9E-BD69-4330-9624-125D961FA675Q48049656-C75F4B39-BA6A-4F2D-84AA-80C897FC2665Q48260240-17DAF5FF-08CD-476E-BBDE-985F56F7B8A6Q48289579-970EA6C1-31F4-4789-BDBE-F8651CD3040EQ50217783-5ED94182-23AC-4487-8366-775725B42AE5Q50440802-830C0C23-00DE-47B3-91A4-A3AD8DDA9AD4Q51185139-A9AD085B-63A2-4900-983C-1270FA2390A7Q51738941-AE831085-109E-43A8-9636-BF2B881D9BD4Q55003664-BCB05DA5-5C80-4552-AD63-005931E396D9Q56890125-3C8D4007-1692-4260-A2AE-5EB6CAE11C13
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Tumor refractoriness to anti-VEGF therapy
@ast
Tumor refractoriness to anti-VEGF therapy
@en
Tumor refractoriness to anti-VEGF therapy
@nl
type
label
Tumor refractoriness to anti-VEGF therapy
@ast
Tumor refractoriness to anti-VEGF therapy
@en
Tumor refractoriness to anti-VEGF therapy
@nl
prefLabel
Tumor refractoriness to anti-VEGF therapy
@ast
Tumor refractoriness to anti-VEGF therapy
@en
Tumor refractoriness to anti-VEGF therapy
@nl
P2860
P3181
P356
P1433
P1476
Tumor refractoriness to anti-VEGF therapy
@en
P2860
P3181
P356
10.18632/ONCOTARGET.8694
P407
P5008
P577
2016-04-11T00:00:00Z
2016-07-19T00:00:00Z